Momenta Pharmaceuticals Inc (MNTA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Craig A. Wheeler
Employees:
131
675 WEST KENDALL STREET, CAMBRIDGE, MA 02142
617 491-9700

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Momenta Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune disease. It sells its products include Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 6.243 Billion Shares Outstanding118.965 Million Avg 30-day Volume 3.558 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.82
Price to Revenue131.4869 Debt to Equity0.0 EBITDA-231.277 Million
Price to Book Value10.0023 Operating Margin-769.5531 Enterprise Value3.503 Billion
Current Ratio6.377 EPS Growth0.094 Quick Ratio6.083
1 Yr BETA 1.3605 52-week High/Low 0.0 / Profit Margin-757.6151
Operating Cash Flow Growth-3.8456 Free Cash Flow to Firm (FCFF) TTM -139.902 Million Free Cash Flow to Equity (FCFE) TTM-163.704 Million
Altman Z-Score14.9755
View SEC Filings from MNTA instead.

View recent insider trading info

Momenta Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MNTA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MNTA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2020-10-01 by STONER ELIZABETH
  • 4: filed on 2020-10-01 by GROGAN DONNA ROY
  • 4: filed on 2020-10-01 by GILMAN STEVEN C
  • 4: filed on 2020-10-01 by GEMAYEL GEORGES
  • 4: filed on 2020-10-01 by DOWNEY BRUCE
  • 4: filed on 2020-10-01 by MANNING ANTHONY M.
  • 4: filed on 2020-10-01 by KWON YOUNG
  • 4: filed on 2020-10-01 by FIER IAN
  • 4: filed on 2020-10-01 by BELTRAMELLO JO ANN
  • 4: filed on 2020-10-01 by ARROYO SANTIAGO

    • Events (8k)

  • 8-K: filed on 2020-10-01:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-06-24:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2020-06-15:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-05-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-04-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-04-02:
    Item 8.01: Other Events
  • 8-K: filed on 2020-02-26:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-01-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DOWNEY BRUCE

    • Director
    		 No longer subject to file 2020-10-01 0

    GEMAYEL GEORGES

    • Director
    		 No longer subject to file 2020-10-01 0

    GILMAN STEVEN C

    • Director
    		 No longer subject to file 2020-10-01 0

    STONER ELIZABETH

    • Director
    		 No longer subject to file 2020-10-01 0

    CARVAJAL ALEJANDRA CHIEF LEGAL OFFICER

    • Officer
    		 No longer subject to file 2020-10-01 0

    GUTIERREZ-RAMOS JOSE-CARLOS

    • Director
    		 No longer subject to file 2020-10-01 0

    ARROYO SANTIAGO SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 No longer subject to file 2020-10-01 0

    MANNING ANTHONY M. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 No longer subject to file 2020-10-01 0

    KWON YOUNG CHIEF FINANCIAL & BUS. OFFICER

    • Officer
    		 No longer subject to file 2020-10-01 0

    BARLOW JANE F

    • Director
    		 No longer subject to file 2020-10-01 0

    FIER IAN CHIEF MFG AND PROGRAM OFFICER

    • Officer
    		 No longer subject to file 2020-10-01 0

    BELTRAMELLO JO ANN CHIEF HR AND INF. OFFICER

    • Officer
    		 No longer subject to file 2020-10-01 0

    GROGAN DONNA ROY

    • Director
    		 No longer subject to file 2020-10-01 0

    CIEPLINSKA AGNIESZKA CHIEF ACCOUNTING OFFICER (PAO)

    • Officer
    		 No longer subject to file 2020-10-01 0

    WHEELER CRAIG A PRESIDENT & CEO

    • Officer
    • Director
    		 No longer subject to file 2020-09-10 0

    ROBERTSON MICHELLE CHIEF FINANCIAL OFFICER

    • Officer
    		 6,813 2019-10-25 0

    SULAT JAMES R

    • Director
    		 54,090 2019-06-19 0

    KOESTLER THOMAS P

    • Director
    		 15,590 2019-06-19 0

    FISHMAN COREY N.

    • Director
    		 10,090 2019-06-19 0

    KAUNDINYA GANESH VENKATARAMAN COO & CSO

    • Officer
    		 495,145 2018-08-21 0

    LEICHER BRUCE SVP & GENERAL COUNSEL

    • Officer
    		 171,801 2018-08-21 0

    STORER SCOTT M SVP, CFO

    • Officer
    		 44,783 2018-02-12 0

    OTTMER MATTHEW P. CHIEF OPERATING OFFICER

    • Officer
    		 0 2017-02-07 0

    SHEA RICHARD P SVP, CFO

    • Officer
    		 119,906 2016-12-15 0

    ROACH JAMES M. SENIOR VP, DEVELOPMENT AND CHI

    • Officer
    		 155,381 2016-11-21 0

    FANUCCI MARSHA

    • Director
    		 14,500 2016-06-23 0

    SHAPIRO BENNETT M

    • Director
    		 10,834 2016-06-01 0

    BISHOP JOHN E SENIOR VP, PHARMACEUTICAL SCIE

    • Officer
    		 157,253 2016-05-19 0

    FRANKEN MICHAEL PRESIDENT, BIOSIMILARS BUSINES

    • Officer
    		 37,968 2015-12-11 0

    CLARKE JOHN K

    • Director
    		 0 2015-06-10 0

    HUTT PETER BARTON

    • Director
    		 6,725 2014-09-12 0

    BRUGGER STEPHEN B CHIEF OPERATING OFFICER

    • Officer
    		 264,918 2010-10-28 0

    SASISEKHARAN RAM

    • Director
    		 306,344 2010-07-26 0

    CRANE ALAN L

    • FORMER DIRECTOR
    		 No longer subject to file 2010-04-14 0

    LANGER ROBERT

    • Director
    		 950,022 2008-08-08 0

    BARRETT PETER

    • Director
    		 0 2008-06-05 0

    REEDERS STEPHEN T

    • Director
    		 483,157 2008-03-27 0

    WHORISKEY SUSAN K V.P., LIC. & BUS. DEV.

    • Officer
    		 68,831 2007-04-17 0

    NOVARTIS AG

    • 10% Owner
    		 4,708,679 2006-07-25 0

    GOLDENHEIM PAUL D

    • Director
    		 0 2006-05-29 0

    LISA CARRON SHMERLING V.P., LEGAL AFFAIRS

    • Officer
    		 0 2006-04-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund MNTA -2.0 shares, $-54.4 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments